Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
This study has been completed.
Study NCT00199901   Information provided by Ludwig Institute for Cancer Research

First Received on September 16, 2005.   Last Updated on February 27, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
NY-ESO-1 ISCOMATRIX®
ISCOMATRIX® adjuvant
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Ludwig Institute for Cancer Research
Cancer Research Institute


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services